Results 71 to 80 of about 13,555 (204)
Antioxidants, 2023 Peritoneal dialysis (PD) is a current replacement therapy for end-stage kidney diseases (ESKDs). However, long-term exposure to PD fluids may lead to damage of the peritoneal membrane (PM) through mechanisms involving the activation of the inflammatory ...
Vanessa Marchant +13 more
doaj +1 more source
Correction: Regulation of MYC Expression and Differential JQ1 Sensitivity in Cancer Cells
PLOS ONE, 2015 There is an error in Fig 2 that appears to have occurred during the preparation of files after the manuscript was accepted. In Fig 2B, the blot for Brd4 incorrectly appears as a duplicate of P-Brd4. The authors have provided a corrected version of Fig 2 here. Fig 2 Brd4 occupancy and expression in different cells.
Trent Fowler +8 more
openaire +3 more sources
JQ1 enhances the effects of HDAC3 depletion.
, 2014 A significant increase in GFP protein expression from the HIV-1 promoter was observed in 2D10 cells that had been depleted of HDAC3 and had been treated with JQ1 (50 nM) for 24 hours over cells that were transduced with the scrambled shRNA control and ...
Kirston M. Barton (618002) +8 more
core +1 more source
Harnessing ferroptosis from multilayer defense networks to nanoplatforms for specific cancer therapy
BMEMat, EarlyView.Nanomaterials target metabolically‐regulated ferroptosis for cancer therapy. Iron‐based or alternative nanoplatforms integrate ferroptosis with chemotherapy, immunotherapy, or radiotherapy. They enable stimulus‐responsive therapies (photothermal, photodynamic, sonodynamic) activated by near‐infrared, light, or ultrasound, achieving potent synergistic ...
Xinyue Xu +5 more
wiley +1 more source
The BET-bromodomain inhibitor JQ1 mitigates vemurafenib drug resistance in melanoma
Melanoma Research, 2018 Inhibition of BRAF improves therapeutic efficacy of BRAF-mutant melanoma. However, drug resistance to BRAF inhibitor is inevitable, and the drug resistance mechanisms still remain to be elucidated. Here, BRAFV600E mutant cells A375 and SK-MEL-28 were chosen and treated with BRAF inhibitor vemurafenib, and the results showed that the ERK signaling ...
Zhao, Bei, Cheng, Xiankui, Zhou, Xiyuan
openaire +3 more sources
JQ1 suppresses tumor growth via PTEN/PI3K/AKT pathway in endometrial cancer [PDF]
, 2016 Overexpression of c-Myc is associated with worse outcomes in endometrial cancer, indicating that c-Myc may be a promising target for endometrial cancer therapy.
Clark, Leslie H. +9 more
core +1 more source
Pharmacokinetic studies of (+)-JQ1, SAHA, and 009P1 in mice.
, 2023 Pharmacokinetic studies of (+)-JQ1, SAHA, and 009P1 in mice.
Tran Phuc (3948350) +10 more
core +1 more source
Bewertung der Kombinationsbehandlung Docetaxel und JQ1 in präklinischen 2D- und 3D-Modellen von Prostatakrebs [PDF]
, 2023 Prostate cancer (PCa) remains the most prevalent cancer in men globally, with an increasing burden worldwide. PCa is unique in its dependence on androgen-androgen receptor (AR) signaling for growth and progression, and hormonal therapies have greatly ...
Xu, Yipeng
core +1 more source
BMEMat, EarlyView.This review comprehensively summarizes emerging biomaterial‐based strategies and underlying mechanisms for modulating endogenous tendon stem/progenitor cells (TSPCs). It offers the most recent insights into TSPC physiology and potential applications of tissue engineering and regenerative medicine in tendons.
Zeyu Zhu +9 more
wiley +1 more source
International Journal of Nanomedicine, 2022 Bowei Chen,1,* Xiaohong Liu,1,* Yunan Li,1 Tianhe Shan,1 Liya Bai,1 Chunyu Li,2 Yinsong Wang1 1School of Pharmacy, Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics (Theranostics), Tianjin ...
Chen B +6 more
doaj